NCT05523661View on ClinicalTrials.gov

Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

March 1, 2025

Study Completion Date

September 1, 2025

Conditions
Ph Positive ALLCAR-T CellDasatinib
Interventions
DRUG

Dasatinib plus anti-CD19/CD22 CAR-T cells

Dasatinib plus VP chemotherapy was administrated to newly diagnosed Ph-positive patients aged 55-70 years old,if hCR was achieved,autolymphocyte was collected,and anti-CD19/CD22 CAR-T cells infusion was administrated to patients followed by Fludarabine and Cyclophosphamide therapy

Trial Locations (1)

Unknown

RECRUITING

Shanghai General Hospital, Shanghai

All Listed Sponsors
lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT05523661 - Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients | Biotech Hunter | Biotech Hunter